Aetos is interested in partnering on biosimilar or innovator molecule in the Oncology and Auto-immune therapeutic areas. We are currently evaluating the following types of partnerships:

  • Co-Development
  • Licensing
  • Clinical development
  • Manufacturing
  • Commercialization

AETOS-partnership-model

Benefits of partnership with Aetos Biologics:

  • Aetos has acquired exclusive license to world class Celltheon SMARTTM Expression Platform technology for development of biosimilars
  • Celltheon SMARTTM Expression Platform has been validated on several clinical stage molecules
  • The team has experience across cell line development, process development, manufacturing and regulatory filling
  • The team consists of industry veterans that have experience developing multiple innovator/ Biosimilar molecules
  • Expertise with US IND and EU IMPD filling
  • Short timeline to regulatory filling to approval